Clinical trials: Placebo Response
Primary Biliary Cholangitis
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).
- Trial name
- NCT03742973
- Testing
- Baricitinib
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Hemodynamic Stability Post Intubation in Laryngoscopy Surgery
Intravenous Lignocaine vs Placebo
To assess the mean hemodynamic responses post-intubation in patients given intravenous lignocaine pre-intubation as compared to a placebo pre-intubation in patients undergoing laryngoscopy surgery
- Trial name
- NCT03787069
- Where
- Pakistan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Indus Hospital and Health Network
Rheumatoid Arthritis
A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate
The primary objective of this study is to evaluate the effects of CKD-506 on signs and symptoms of RA in subjects with moderate-to-severe RA who are inadequate responders to methotrexate.
- Trial name
- NCT04204603
- Testing
- CKD-506
- Where
- 38 sites in Czechia, Georgia and 3 more
- Volunteers
- 122 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines
It is thought that vaccines trigger innate inflammatory responses to induce antigenspecific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side…
- Trial name
- NCT01765413
- Testing
- Varicella-zoster virus, Yellow Fever Vaccine
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Chronic Low-back Pain
Cognitive Functional Therapy Compared With Sham-treatment for Low Back Pain
Chronic low back pain is a public health problem, and there is strong evidence that it is associated with a complex interaction of biopsychosocial factors.
- Trial name
- NCT04518891
- Testing
- Cognitive Functional Therapy (CFT)
- Where
- Brazil
- Volunteers
- 152 people
- Sponsor
- University of Sao Paulo
Type 2 Diabetes
Dose Response Study in Japanese Patients
This is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT00261417
- Testing
- Tesaglitazar
- Where
- 20 sites in Japan
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Benign Prostatic Hyperplasia
Study of the Effects of Pomegranate Tablets on Enlarged Prostates
To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia.
- Trial name
- NCT00381108
- Testing
- Pomegranate Tablet
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Immune Thrombocytopenia (ITP)
Rituximab as Second Line Treatment for ITP
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized thrombocytopenia. Splenectomy is the standard treatment for patients who fails the first-line treatment: corticosteroid.
- Trial name
- NCT00344149
- Testing
- Rituximab (Mabthera)
- Where
- Norway
- Volunteers
- 112 people
- Sponsor
- Ostfold Hospital Trust
Fibromyalgia
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia
The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple…
- Trial name
- NCT01014585
- Testing
- Milnacipran
- Where
- 58 sites in United States
- Volunteers
- 340 people
- Sponsor
- Forest Laboratories
Primary Biliary Cholangitis
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.
- Trial name
- ELSPIRE (NCT06383403)
- Testing
- Elafibranor
- Where
- 60 sites in United States, Czechia and 8 more
- Volunteers
- 92 people
- Sponsor
- Ipsen
Resistant Depression, Treatment, Bipolar Depression
Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression
Theta Burst Transcranial Magnetic Stimulation (TBS) in dorsolateral prefrontal cortex (DLPFC) has shown efficacy and safety as an adjuvant strategy for resistant to treatment depression (RTD) in daily sessions during 4-6 weeks…
- Trial name
- EMTtfNI (NCT04998773)
- Testing
- Theta Burst Transcranial Magnetic Bilateral Stimulation, Theta Burst Transcranial Magnetic Unilateral Stimulation
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Chronic Idiopathic Urticaria
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment…
- Trial name
- NCT01292473
- Testing
- Omalizumab
- Where
- 61 sites in United States, Denmark and 6 more
- Volunteers
- 323 people
- Sponsor
- Genentech, Inc.
Allergic Rhinitis
Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)
The purpose of this study is to see whether ASP-1001 when given as a nasal spray is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever) following nasal challenge with antigen.
- Trial name
- NCT00791102
- Testing
- ASP-1001 nasal spray
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older
The purpose of this clinical study was to evaluate immune responses measuring antibodies in serum and secretions and cellular immune responses generated by CAIV-T vaccine in healthy adults aged 18 years and older as a means to…
- Trial name
- NCT00192153
- Testing
- CAIV-T or TIV
- Where
- 2 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Asthma
Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from…
- Trial name
- NCT01128569
- Testing
- Fluticasone Furoate, FF/Vilanterol (VI; GW642444M)
- Where
- 4 sites in Germany, New Zealand and 1 more
- Volunteers
- 52 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240121
- Testing
- Rifaximin EIR
- Where
- 72 sites in United States
- Volunteers
- 80 people
- Sponsor
- Bausch Health Americas, Inc.
COVID-19
INB03 for the Treatment of Pulmonary Complications From COVID-19
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
- Trial name
- NCT04370236
- Testing
- INB03
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- Inmune Bio, Inc.
Subfertility
DHEA Versus Placebo in Women With Poor Ovarian Response
440 women with expected poor ovarian response undergoing IVF/ICSI (intracytoplasmic sperm injection) will be randomly divided into 2 groups using computer generated random numbers .
- Trial name
- DHEA (NCT02561793)
- Testing
- DHEA
- Where
- 2 sites in Egypt
- Volunteers
- 440 people
- Sponsor
- Cairo University
Healthy Male Adults
Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Oxytocin (OT) is a small, naturally occurring peptide currently in clinical use to stimulate lactation in breastfeeding women. The intranasal administration of OT has recently attracted attention as a potential novel treatment in…
- Trial name
- NCT01983514
- Testing
- 8IU intranasal oxytocin, 24 IU intranasal oxytocin, 1 IU intravenous oxytocin
- Where
- Norway
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- OptiNose AS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.